Galinpepimut-S is a Subunit Vaccine owned by SELLAS Life Sciences Group, and is involved in 14 clinical trials, of which 6 were completed, and 8 are ongoing.
Galinpepimut-S elicits anti-neoplastic properties by stimulating the immune system. The therapeutic candidate induces a WT1-specific cytotoxic T-lymphocyte response against WT1 expressing cells, thereby resulting in cell lysis and destruction of the cancer cells expressing WT1. The therapeutic candidate by killing the cancer cells may check the progression of disease.
The revenue for Galinpepimut-S is expected to reach a total of $692m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Galinpepimut-S NPV Report.
Galinpepimut-S is under development for the treatment of acute myelocytic leukemia (AML), acute lymphocytic leukemia (ALL), lung cancer, solid tumor, malignant pleural mesothelioma, multiple myeloma, ovarian cancer, colorectal cancer, triple-negative breast cancer, small-cell lung cancer, fallopian tube or primary peritoneal cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, diffuse large B-cell lymphoma, follicular lymphoma and myelodysplastic syndrome. It is formulated as an emulsion or solution and administered subcutaneously and parenterally. It is a synthetic peptide vaccine consisting of the immunogenic amino acids of the human Wilms tumor protein-1 peptides which include WT-1 A1, WT-1 122 long, WT-1 427 long and WT-1 331 long. The therapeutic candidate targets Wilms tumor protein 1 (WT1). It was also under development for the treatment of chronic myeloid leukemia (CML) and glioblastoma multiforme.
SELLAS Life Sciences Group Overview
SELLAS Life Sciences Group (SELLAS), formerly Galena Biopharma, develops novel cancer immunotherapeutics for multiple cancer treatments. Its pipeline product candidates include galinpepimut-S (GPS), a wilms tumor1 (WT1) protein-targeting synthetic heteroclitic epitope immunotherapeutic antigen used for the treatment of acute myeloid leukemia, ovarian cancer, malignant pleural mesothelioma, multiple myeloma and solid tumors; and Nelipepimut-S, a vaccine derived from the human epidermal growth factor 2 or HER2 protein for the prevention of breast cancer and gastric carcinomas. The company collaborates with Memorial Sloan Kettering Cancer Center (MSKCC), National Cancer Institute (NCI) and The University of Texas M.D. Anderson Cancer Center (MDACC) for conducting clinical trials targeting multiple cancer indications. SELLAS is headquartered in New York City, New York, the US.
The company reported revenues of (US Dollars) US$7.6 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$1.9 million in FY2020. The operating loss of the company was US$25.3 million in FY2021, compared to an operating loss of US$17 million in FY2020. The net loss of the company was US$20.7 million in FY2021, compared to a net loss of US$16.8 million in FY2020.
Quick View – Galinpepimut-S
|Highest Development Stage|